RFPによる肝障害

概要

論文の詳細を見る
Rifampicin (RFP)-induced liver dysfunction during the treatment for tuberculosis was discussed.<BR>Incidence of RFP-induced liver dysfunction was 11.1 % (151 cases) among 1, 359 cases treatedwith RFP-containing regimens.<BR>Many of the RFP-induced liver dysfunction were observed in the early stage of chemotherapy, and the elevation of serum transaminases (s-GOT and s-GPT) was mild in the majority of cases. Asthe recovery was retarded among cases with s-transaminases above 100 K-U than cases below 100, the former RFP should be discontinued in the former until the restoration of liver dysfunction.<BR>Attention should be payed to the cases with elevated s-transaminases combined with abnormalitiesof other laboratory data such as ZnTT, history of other liver dysfunction, diabetes mellitus or habitualdrinkings, as the recovery of liver dysfunction is retarded in such cases.<BR>The liver dysfunction as one of the side-effects should be given proper attention in the treatmentfor tuberculosis, considering long-term benefit of patients.
一般社団法人日本結核病学会の論文